title: Targeted therapy for cutaneous oncology: a review of novel treatment options for non-melanoma skin cancer: part II.
abstract: The field of cutaneous oncology is exploding with innovative treatment options, specifically in the field of targeted therapy. These advances offer new hope to select patients with high risk skin cancers. In part two of our series on targeted therapy for skin cancer, we focus our attention on squamous cell carcinoma. We begin with the epidermal growth factor receptor inhibitors and branch out into newer areas of active research.
authors.forename: Brooke
authors.initials: B
authors.lastname: Walls
authors.forename: Laura
authors.initials: L
authors.lastname: Jordan
authors.forename: Lisa
authors.initials: L
authors.lastname: Diaz
authors.forename: Richard
authors.initials: R
authors.lastname: Miller
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002280:Basal Cell Carcinoma / Q000188:drug therapy / Q000235:genetics; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000235:genetics; D002986:Clinical Trials as Topic; D003880:Dermatology / Q000639:trends; D004815:Epidermal Growth Factor / Q000037:antagonists & inhibitors; D006801:Humans; D058990:Molecular Targeted Therapy; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000235:genetics
chemical_list: D000970:Antineoplastic Agents; D004815:Epidermal Growth Factor